Sam Klempner, MD, Massachusetts General Hospital


Dr. Klempner on the Results of the DisTinGuish Trial in Advanced Gastroesophageal Adenocarcinoma

February 1st 2022

Sam Klempner, MD, discusses the results of the ongoing phase 2a DisTinGuish trial in advanced gastroesophageal adenocarcinoma.

ESMO 2021 Updates in Gastric Cancer and Colorectal Cancer

December 6th 2021

Sam Klempner, MD; Daniel H. Ahn, DO; Nataliya V. Uboha, MD, PhD; and Manish A. Shah, MD, FASCO, review recent updates in second-line gastric cancer, CAR T-cell therapy in solid tumors, and colorectal cancer presented at ESMO 2021.

ESMO 2021 Updates in HER2+ Metastatic Gastric and Gastroesophageal Cancer

November 29th 2021

Key opinion leaders in gastric cancers comment on ESMO 2021 updates in metastatic HER2+ esophagogastric adenocarcinoma and metastatic HER2+ gastric or gastroesophageal junction cancer.

ESMO 2021 Updates in Gastroesophageal and Gastric Adenocarcinomas

November 22nd 2021

Drs Sam Klempner, Nataliya V. Uboha, Daniel H. Ahn, and Manish A. Shah discuss recent data presented at ESMO 2021 for metastatic or locally advanced gastroesophageal and gastric adenocarcinomas.

ESMO 2021 Updates in Metastatic Esophageal Squamous Cell Carcinoma

November 15th 2021

Experts in gastrointestinal cancers review recent updates and clinical implications from phase 3 trials presented at ESMO 2021 in metastatic esophageal squamous cell carcinoma (ESCC).

Emerging Agents and Biomarkers in Gastric and GEJ Cancers 

August 2nd 2021

Daniel Catenacci, MD, and Sam Klempner, MD, conclude their discussion by examining emerging agents and biomarkers for the management of advanced gastric and esophagogastric junction cancers.

Sequencing After Progression on IO-Based Therapy for mGC

August 2nd 2021

Experts in the management of gastric cancer discuss best practices for monitoring signs and symptoms of disease progression and explore factors to consider when switching therapies in later lines of treatment.

Frontline Therapy for Metastatic PD-L1–, HER2+ Gastric Cancer

August 2nd 2021

Gastric cancer specialists emphasize the importance of communication and education when selecting first-line treatment for patients with PD-L1-negative, HER2-positive disease.

Biomarker Testing for Gastric and GEJ Cancers 

July 26th 2021

Experts in gastrointestinal oncology review the challenges associated with molecular testing and the role of biomarker testing on disease management. 

KEYNOTE-811: IO-Based Therapy for HER2+ Gastric Cancer

July 26th 2021

Sam Klempner, MD, and Daniel Catenacci, MD, discuss the KEYNOTE-811 study of pembrolizumab plus trastuzumab in combination with chemotherapy in patients with HER2-positive disease.

CHECKMATE649: Safety Profile and Toxicity Management

July 19th 2021

Thought leaders in gastric and GEJ cancers review safety outcomes from the CHECKMATE649 trial presented at the 2021 ASCO annual meeting.

CHECKMATE649: Trial Design and Efficacy Data

July 19th 2021

Key opinion leader in gastric cancer, Daniel Catenacci, MD, leads a discussion on the study design, patient population, and results from the CHECKMATE649 trial of nivolumab and chemotherapy in patients with gastric or GEJ cancers.

Recent FDA Approvals in Gastric and GEJ Cancers

July 12th 2021

Daniel Catenacci, MD, and Sam Klempner, MD, consider the overall impact of recently approved immunotherapy-based regimens for gastric and gastroesophageal junction cancers.

Historical Perspective on Treatment of Gastric and GEJ Cancers 

July 12th 2021

Experts in the management of gastric cancer provide a historical perspective on available treatment options.